rectal cancer – Medxy AI

Multidisciplinary Late Sequelae Clinics in Managing Low Anterior Resection Syndrome: A Prospective Cohort Study

By MedXY 10/10/2026

A prospective cohort study demonstrates that a specialized multidisciplinary approach combining surgical and gastroenterological treatments significantly improves bowel function and quality of life in patients with low anterior resection syndrome after rectal cancer surgery.

General Surgery news Oncology

Reevaluating Management Strategies for Downstaged Lateral Pelvic Lymph Nodes in Rectal Cancer under Total Neoadjuvant Therapy

By MedXY 10/05/2026

This article reviews outcomes in rectal cancer patients with initially positive lateral pelvic lymph nodes that completely respond to total neoadjuvant therapy, highlighting comparable oncologic results to node-negative patients and implications for management and organ preservation.

AI news Oncology

AI Model Shows Moderate Accuracy for Predicting Complete Response After Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer

By MedXY 06/08/2026

A fine-tuned ensemble of tabular foundation models moderately predicted pathological complete response after TNT and showed potential to support watch-and-wait selection after recalibration.

Gastroenterology news Oncology

Adherence to Surveillance in the Watch and Wait Approach for Rectal Cancer

By MedXY 05/08/2026

Study finds 62% of rectal cancer patients on Watch and Wait receive optimal surveillance, with younger patients showing better adherence. Critical gaps occur in the first year, particularly in initial endoscopic/imaging exams and colonoscopies.

General Surgery news Oncology

Rectal Cancer Accreditation Was Linked to Higher Hospital Volume Without More Care Fragmentation

By MedXY 05/08/2026

A national difference-in-differences study found NAPRC accreditation was associated with modest growth in rectal cancer volume and stage I procedural volume, without evidence of increased care fragmentation.

General Surgery news Oncology

The Bottom-Up Revolution: How New Surgical Techniques are Saving Lives and Lifestyles in Rectal Cancer

By MedXY 03/18/2026

A groundbreaking North American trial reveals that the taTME 'bottom-up' surgical approach for rectal cancer offers a 93.7% three-year survival rate and allows 97% of patients to remain stoma-free, fundamentally changing the landscape of pelvic surgery.

Gastroenterology news Oncology

Personalizing Neoadjuvant Intensity: 5-Year CinClare Data Validate UGT1A1-Guided Irinotecan for Rectal Cancer

By MedXY 01/14/2026

The 5-year update of the CinClare trial demonstrates that adding irinotecan to neoadjuvant chemoradiotherapy, guided by UGT1A1 genotype, significantly improves long-term survival and disease-free outcomes in patients with locally advanced rectal cancer.

General Surgery news Oncology

A 30-Day Mortality Risk Score After Proctectomy for Rectal Cancer: What the NCDB Tells Us and How to Use It

By MedXY 12/02/2025

A validated NCDB-derived risk score using age, sex, race, comorbidity, stage, neoadjuvant therapy, length of stay and conversion identifies patients at markedly different 30-day mortality risk after proctectomy (0.8%–4.5%).

Gastroenterology news Oncology

Total Neoadjuvant Therapy Enables Organ Preservation Without Compromising Distant Control in pMMR/MSS Stage II–III Rectal Cancer: Insights from the NO-CUT Trial

By MedXY 11/29/2025

The NO-CUT phase 2 trial shows that total neoadjuvant therapy (CAPOX-based TNT) followed by non-operative management for clinical complete responders achieved high 30‑month distant relapse‑free survival (95%) and enabled organ preservation in 26% of patients with pMMR/MSS stage II–III rectal cancer.

Oncology Specialties

Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Real-World Insights from an International Consortium

By MedXY 08/23/2025

This international multicenter study evaluates total neoadjuvant therapy (TNT) in routine clinical practice for stage II/III rectal adenocarcinoma, demonstrating varied regimen use and confirming TNT’s efficacy across treatment strategies.

Oncology Radiology Specialties

Dual Immune Checkpoint Blockade with Neoadjuvant Chemoradiotherapy in Rectal Cancer: Insights from the CHINOREC Trial

By MedXY 08/23/2025

The CHINOREC phase 2 trial demonstrates that adding ipilimumab and nivolumab to standard neoadjuvant chemoradiotherapy in rectal cancer is safe and feasible, showing promising clinical activity but no significant improvement in complete response rates.

Clinical Updates General Surgery Oncology Specialties

Advancing Organ Preservation in Locally Advanced Rectal Cancer: Insights from the CAO/ARO/AIO-16 Phase 2 Trial

By MedXY 08/14/2025

Total neoadjuvant therapy combined with watch-and-wait strategies achieves a 37% clinical complete response rate in locally advanced rectal cancer with manageable toxicity, offering an organ-preserving alternative to surgery.

Clinical Updates news Oncology Specialties

Short-Course Radiotherapy Plus Sintilimab and Chemotherapy as Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer: Insights from the SPRING-01 Trial

By MedXY 08/02/2025

Adding sintilimab to short-course radiotherapy and chemotherapy significantly increased pathological complete response rates in locally advanced rectal cancer, with manageable safety.